Results 71 to 80 of about 255,512 (289)

Knowledge domains and emerging trends in immune-related adverse events from immune checkpoint inhibitors: A bibliometrics and visualized analysis

Heliyon
Objective: The primary objective of this paper is to investigate the research hotspots and future trends of immune-related adverse events induced by immune checkpoint inhibitors, offering valuable insights for researchers in this field.
Jun Zhao, Yujie Feng, Guang-wei Liu
doaj   +1 more source

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy

Frontiers in Oncology, 2022
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs)
Sebastian Bruera, Maria E. Suarez-Almazor   +1 more
doaj   +1 more source

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. [PDF]

, 2019
Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhibitors (ICIs) including, but not limited to ...
Adashek, Jacob J, Galanina, Natalie, Junior, Pedro Nazareth Aguiar, Kurzrock, Razelle   +3 more
core  

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). [PDF]

, 2018
The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing rapidly due to growing proportion of HPV-related disease and development of new therapeutic agents.
Jung, Kyungsuk, Kang, Hyunseok, Mehra, Ranee   +2 more
core   +2 more sources

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma

Frontiers in Oncology, 2021
Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer (NSCLC) for which there is currently no recognized treatment.
Zuohong Wu, Xinghong Xian, Ke Wang, Deyun Cheng, Weimin Li, Bojiang Chen   +5 more
doaj   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

EDNRB‐dependent endothelin signaling reduces proliferation and promotes proneural‐to‐mesenchymal transition in gliomas

Molecular Oncology, EarlyView.
Glioma cells mainly express the endothelin receptor EDNRB, while EDNRA is restricted to a perivascular tumor subpopulation. Endothelin signaling reduces glioma cell proliferation while promoting migration and a proneural‐to‐mesenchymal transition associated with poor prognosis. This pathway activates Ca2+, K+, ERK, and STAT3 signalings and is regulated
Donovan Pineau, Leonor Garcia, Hugo Arnold, Antonija Hanžek, Maialen Arrieta, Laurent R Gauthier, Christine Granotier‐Beckers, François D Boussin, Amaury Herbet, Marie Hautière, Valentin Asei‐Ceschino, Clémentin Jacques, Laura Brard, Thomas Harnois, Valérie Coronas, Bruno Constantin, Aurélien Chatelier, Jean Chemin, Serge Urbach, Martial Seveno, Szimonetta Hideg, Chantal Ripoll, Kasandra Aguilar‐Cázarez, Min Zheng, Guo‐Hao Huang, Sheng‐Qing Lv, Lei Zhang, Philippe Rondard, Laurent Prezeau, Jean‐Philippe Pin, Hugues Duffau, Luc Bauchet, Valérie Rigau, Franck Denat, Charles Truillet, Didier Boquet, Jean‐Philippe Hugnot   +36 more
wiley   +1 more source

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies

Journal for ImmunoTherapy of Cancer, 2020
In the last few years, the unprecedented results of immune checkpoint inhibitors have led to a paradigm shift in clinical practice for the treatment of several cancer types.
Alberto Puccini, Maria Laura Iaia, Mohamed E Salem   +2 more
doaj   +1 more source

Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. [PDF]

, 2017
Cancer-Testis antigens (CTA) are immunogenic molecules with normal tissue expression restricted to testes but with aberrant expression in up to 30% of non-small cell lung cancers (NSCLCs). Regulation of CTA expression is mediated in part through promoter
Barnett, Stephen A, Boutros, Paul C, Chüeh, Anderly C, Jayachandran, Aparna, John, Thomas, Liew, Mun-Sem, Mariadason, John M, Russell, Prudence A, Starmans, Maud HW, Walkiewicz, Marzena, Wright, Gavin   +10 more
core   +2 more sources